Good morning, everyone, and welcome to HealthSouth's Second Quarter 2015 Earnings Conference Call. At this time, I would like to inform all participants that their lines will be in a listen-only mode. After the speakers' remarks, there will be a question-and-answer period. [Operator Instructions] You will be limited to one question and one follow-up question. Today's conference call is being recorded. If you have any objections, you may disconnect at this time. I would now like to turn the conference over to Mary Ann Arico, Chief Investor Relations Officer.

Thank you, Hope, and good morning everyone. Thank you for joining us today for the HealthSouth second quarter 2015 earnings call. With me on the call today in Birmingham are Jay Grinney, President and Chief Executive Officer; Doug Coltharp, Chief Financial Officer; Mark Tarr, Chief Operating Officer; John Whittington, General Counsel and Corporate Secretary; Andy Price, Chief Accounting Officer; Ed Fay, Treasurer; Julie Duck, Senior Vice President of Financial Operations and Ross Before we begin, if you do not already have a copy of the second quarter earnings release, financial statements, the related 8-K filing with the SEC and the supplemental slides are available on our website at www.healthsouth.com. Moving to slide 2, the Safe Harbor which is also set forth in greater detail on the last page of the earnings release. During the call, we will make forward-looking statements which are subject to risks and uncertainties, many of which are beyond our control. Certain risks, uncertainties and other factors that could cause actual results to differ materially from management's projections, forecasts, estimates and expectations are discussed in the company's SEC filings including the earnings release and the related 8-K, the Form 10-K for 2014, and the Form 10-Q for second quarter 2015 when filed. We encourage you to read them. You are cautioned not to place undue reliance on estimates, projections, guidance and other forward-looking information presented. Statements made throughout this presentation are based on current estimates of future events and speak only as of today. The company does not undertake a duty to update or correct these forward-looking statements. Our slide presentation and discussion on this call will include certain non-GAAP financial measures. For such measures, reconciliation to the most directly comparable GAAP measure is available at the end of the slide presentation or at the end of the related press release, both of which are available on our website and as part of the Form 8-K filed last night with the SEC. Before I turn it over to Jay, I would like to remind you that we will adhere to the one question and one follow-up question rule to allow everyone to submit a question. If you have additional questions, please feel free to put yourself back in the queue. And with that, I will turn the call over to Jay.

Great. Thank you, Mary Ann. Before we begin, I'd like to re-introduce Ross Comeaux, our new Director of Investor Relations. Something I am embarrassed to say, I should have done at our Investor Day back in June. Ross joined HealthSouth on May 26 and came to us from JP Morgan where he was a sell-side analyst for five years covering medical technology and devices. Prior to JP Morgan Ross was an analyst with RBC Capital Markets and before that BofA. He began his career at PWC as a HealthCare consultant and we are very pleased to have him on the team. He has done an excellent job of moving up the learning curve and acclimating to HealthSouth during his brief tenure with us and will be a tremendous asset as Mary Ann transitions to retirement. Now to our second quarter results. Although there were a lot of moving parts in the quarter that may require some time to digest, we believe there are five key takeaways. First, both segments had a very strong second quarter in terms of volumes. Discharges grew in our inpatient segment by 8.3% while admissions at Encompass locations owned since January 01, 2014 grew 15.9%. Second, Encompass had an exceptionally good quarter. They not only had double digit volume growth, they also did an excellent job of managing their costs, generated $19 million of adjusted EBITDA continued to successfully integrate legacy HealthSouth agencies and added new locations in five markets all of which were markets that over lapped with our hospitals. Third, our inpatient segment adjusted EBITDA was up against two headwinds, of 13.5% comp for the company and $9 million on unusual items. While we obviously can’t forecast when these unusual items will occur it was very disappointing that they happened on the heels of…

Thank you, Jay and good morning, everyone. As was evident from Jay's comments, we’ve got a lot to cover this morning so I’ll jump right into the numbers. On a consolidated basis, Q2 net operating revenues increased by 26.5% and adjusted EBITDA increased by 11% over Q2, 2014 largely owing to the acquisition of Encompass. Diluted EPS for Q2 was $0.47 as compared to $0.81 in Q2 last year. The year-over-year EPS comparison for Q2 was rendered difficult by two items. The gain of $0.26 per share realized in Q2 last year on a fair loan transaction and the $0.11 per share loss on debt extinguishment experienced in Q2 this year related to the completion of the call of the 8.125% senior notes. It’s worth noting that Q2 is our toughest comp consolidated adjusted EBITDA as Q2 2014 increased 13.5% over Q2 2013. And as Jay mentioned in his comments, Q2 was a challenging quarter with strong volume growth for the Europe segment did not flow through to adjusted EBITDA primarily due to lower than expected pricing and an unexpected increase in our group medical insurance reserves. IRF segment revenue rose 8.1% in Q2 2015 over Q2 2014 driven by an 8.3% increase in discharges. Same-store discharges grew 2.8% and new store discharges grew 5.5% approximately 110 basis points of that attributable to the fair loan consolidation with solid contributions from the four new hospitals added in Q4 of last year and the two additional hospitals that came on board in the first half of 2015. Pricing growth for the IRF segment as measured by revenue per discharge was lower than expected at 0.3%. As previously disclosed, Q2 2015 was negatively impacted by approximately $5 million by the updated SSI ratios for 2013 published in the quarter. Conversely, Q2 2014…

[Operator Instruction] Your first question comes from the line of Whit Mayo with Robert Baird

Good morning, Whit.

Hey, thanks for all the color this morning, very appreciated. Just wanted to go back to the mix changes in the rehab business for a second. Just to be clear, these new Medicaid patients and exchange patients really we shouldn't think of this as being dilutive to EBITDA nor are they really displacing the traditional Medicare patients. Is the right way to think of this set this is a tail wind for earnings and a tail wind for volumes but to the detriment of margin and pricing? Again, you don't look at this as a headwind to total growth, do you?

Hey Whit, it’s Doug. I think that the when we look on average and of course the Medicaid reimbursement varies pretty widely from state to state, but on average atleast looking for the first half of this year the reimbursement that we were receiving on Medicare patients was about sufficient to cover our variable cost per day, so they were essentially break even. So what that suggests is that you can see higher volume but a little bit of pressure on the EBITDA margin. These patients are not displacing traditional Medicare or Medicare Advantage patients. So we are not sacrificing EBITDA because the reallocation of existing space to a lower margin patient.

And Whit I would just say is that average clearly has a lot of variability associated with it. In many of the states where we are able to treat Medicaid patients the payments create actual EBITDA and contributes to EBITDA growth where we have the challenge is addressing the Medicaid volumes in those states where as Doug just suggested the payments are inadequate. And that’s a delicate balancing act as I’m sure you can appreciate particularly when we have a partnership and we are getting referrals from their partner we really need to be in a position to treat all comers.

That's helpful. And maybe my second question, just on Reliant. Can you just maybe update us on where the EBITDA run rate is today, and are you planning on rebranding that as a HealthSouth hospital, or are you going to keep the name Reliant? And I guess I'm just kind of curious, what's different about those assets versus your assets, and just maybe help us think about the earnings stream and synergies as we fold that into our model.

Yes we’ll provide the information on earnings and so on once we close. We’re really not in a position to do that since we don’t own the assets quite yet. In terms of the re-branding yes, they will definitely be rebranded as HealthSouth hospitals in those markets. And you know there differences but the real difference is that reflect what we have seen with other acquisitions, specifically in the case of Reliant and other acquisitions the patient mix tends to be more oriented towards orthopaedic and less oriented to the neuro and the stroke populations converting that overtime will be a function of introducing the clinical competencies, introducing necessary new technology but we believe we will be able to do that. You know we know these hospitals, we compete against them today in two instances, Braintree Woburn up in the Massachusetts area, if you recall we used to own those two hospitals. We lost them in a lease dispute and frankly the PE firm was able to clean up a lot of those lease issues as a result of a series of events that really forced a fire sale by the previous owner to the PE firm. Now the PE firm did a very nice job, Nautic partners did a very nice job of getting in, in cleaning that up. So we are very excited to get back into the Greater Boston Metro area and particularly Braintree has quite a fine reputation up there. So there are some similarities, some differences but as I said we’ll provide information on what to expect in terms of incremental EBITDA and so on once we close.

Your next question comes from the line of Ann Hynes with Mizuho Securities.

Good morning, Ann.

Hi. I have a couple of questions. One, on the medical reserve. So, I guess it's a little surprising given you reiterated guidance on June 11. So can you go over your policy and why this was a few weeks later a big uptick? And then my second question is SG&A. Even when we take out that $4 million, SG&A as a percentage of revenue was flat and when I look at my model over the past six years. That typically goes down in Q2. So is there anything else going on with the labor that needs to be pointed out? I'm not sure if it's the Medicaid mix or anything like that. Thanks.

Ann, it’s Doug. To begin on the group medical, there were two things that led to us recognizing that need add to the accrual in the quarter that we found out after the June 10th Investor Day. First is, we’ve received the claims information on that particular severe claim that I mentioned, the high risk delivery in Texas from our TPA after June 10th. And then the second is we were in the process of conducting our semi-annual actuarial update and that occurred after June 10th as well. With regard to the SG&A I don’t think there is anything else specifically to point. I think the impact on the revenue from the SSI adjustment was certainly a factor but it’s not really material difference.

Okay. Thanks.

Your next question comes from the line of A.J. Rice with UBS.

Thanks. Hello, everybody. First off, on these continuing issues around the MACs and the audits, can you give maybe Jay or someone give us any discussions beyond just your back and forth with the MACs trying to get any resolution here, and is there an updated number as to the aggregate amount of funds you have tied up in this at this point?

Let’s me address the first one and I’ll ask Doug to address the second part of that question. We have engaged with the largest MAC that we deal with and we’ve talked about this in the past, there is one MAC handles the claims for 70 plus of our hospitals. And that’s where we have seen the vast majority of the denials. We have had a couple of meetings with them trying to better understand their rationale and their logic for denying these claims and we’re very pleased that they have agreed to sponsor a forum, an education forum in August for all of the rehabilitation providers in their jurisdiction to explain their process for denying these claims. We’re looking forward to that. We think that will be informative. Frankly in the private meetings we've received general information, not specific information. We hope to get more specific information in August. And that information will help us in two areas. First it will help us better understand their process so that we can then to the extent that it is necessary modify any of our internal processes to help eliminate or as Doug said, reduce or eliminate the denials going forward. Secondly, we will get I think meaningful information about they are approaching these, because frankly we based on our meetings believe that rather than following the letter of the law with respect to medical necessity and so on, they are utilizing what it basically amounts to rules of thumb, where medical necessity is not the consideration, it’s a rule of thumb. I’ll give you an example. They as a rule of thumb will deny a simple knee or a simple hip replacement that has no co-morbidities. Irrespective of what the underlying physicians assessment is with respect to that patient’s medical…

Okay. And the order of magnitude?

A.J. its Doug. On that as of the end of June we had a total of 5,408 denied claims were outstanding and that represented approximately $86.6 million of billings, that amount of billings is prior to the reserves we’ve established against those.

All right. Thanks a lot.

Your next question comes from the line of Frank Morgan with RBC Capital Markets

Hello, Frank.

Good morning. I was hoping you could -- obviously with this increase in development activity that you have underway, there's clearly a drag that comes with that, but I was hoping maybe you could give us – I’m not necessarily asking for guidance for next year, but just conceptually, when we think about the magnitude of the drag from development, could you comment in general terms about that and how that was prepared to the underline organic growth rate, the EBITDA growth rate, for both the IRF and the home health segment?

I don’t know at this juncture the drag for the hospitals that came on in Q4 is certainly decreasing as you know in our investor reference book we highlight what that first year ramp up is and on average you get to an EBITDA positive somewhere in that six-month range, so we’re kind of getting to that point for the fourth quarter, hospitals that were open in the fourth quarter. Memorial, Cardinal Hill, a little different story. Those are two hospitals that kind of reflect that mix that I was talking about before that you typically see in other IRFs. The good news is Cardinal Hill is little bit better than what we expected in the second quarter. We hope to be able to continue that going forward. So that kind of characterizes what that drag might be in the second quarter and maybe even the first half the year, not a lot of drag on the home health side. Encompass is very accomplished at getting into these agencies, especially – I mean they are very small, so it’s not they are tackling a huge operation, but they are significant and making the transition is not easy but they do it very, very well. And so there’s not a lot of drag there. There maybe some with the transition from the legacy HealthSouth, but I think that pretty deminimis.

Frank, its Doug. Just to add to that. We only have one new IRF scheduled to come on board this year and that’s the one that we’re opening in your backyard in Franklin, Tennessee in the fourth quarter. And then 2016 is really – 2016 will start to see some additional hospitals come on board and we’ve outlined those on slide six of the supplemental slide. I think the really big focus in terms of what we will be dealing with from an on-boarding perspective is going to be the Reliant transaction and obviously we’ll have a whole lot more to say about that and its potential impact on 2016 once we get to the closing table.

And as you think about the start-up cost and that drag you want to try to quantify it. I don’t have our IRB immediately in front of me, but I believe in the growth section of the IRB we characterize what the typical start-up cost are and what the CapEx is and what the start-up cost are, so if you look at that that will give at least some order of magnitude.

And the organic growth, like putting start-ups aside, just what do you feel like, based on what you know today, the -- we should be modelling on an organic EBITDA growth, just on the base organic same-store business? Thanks.

Yes. I guess it’s way too early to be talking about 2016. We’re focused on completing this year and we’ll provide guidance on 2016 once we get to that point. Obviously, we’ll update the balance of 2015 once we closed on Reliant, but it’s really kind of too early to talk about 2016. I will say we’re very excited about the development pipeline. We’re very excited about the new hospitals that are going to be coming online, very excited about Reliant and we’re very confident that 2016 is going to be a very good year for us.

And we continue to believe that the CAGRs that are represented on our business model slide are appropriate.

Okay, thanks.

Your next question comes from the line of Chris Rigg of Susquehanna Financial Group.

Good morning. Given the mix shift, can you help us right size the payment differential between the payers? So if Medicare fee for service is 100%, how do we think about Medicare Advantage, Medicaid commercial on a per discharge basis?

So, if you look at the Medicare Advantage is about 10%, Managed Care its about 26%, Medicaid is on average about 33%.

Yes. So you are saying 33% -- so you’re getting a dollar…?

It’s a 33% discount, 26% discount, 10% discount off of traditional Medicare.

Perfect. And then, can you give us your thoughts on the initial home health proposal for 2016?

Yes. It’s kind of hard to do that because as you know CMS stated that there was an error in the original case mix weightings. And they said that there was a misalignment between the case mix weights in the payment group. I guess it was Table 9 and that they’re going to be issuing a correction. So until we have that it’s a little bit hard to really access what that rule is going to look like. Overall, our view is that any proposed rule that continues to advanced differentiation among providers based on quality is very good for HealthSouth be it on the IRF side on the Home Health side and certainly that -- this proposal rules does that. And so our initially take is we will wait to see what the pricing effect is going to be, but certainly on the quality metrics whether or not there’s a right quality metric, I mean you can argue all day long on that. But again anything that can – that will advance differentiating providers, based on quality and outcome we believe is very good for our company.

Perfect. Thanks a lot.

Your next question comes from the line of Gary Lieberman with Wells Fargo.

Hey, Gary.

Hey, good morning. Thanks for taking my question. Can you give us your thoughts in terms of strategy for dealing with the mandatory joint replacement program and any risks to volumes from that?

Yes. As I mentioned in my comments the total number of joints that are affected, could possibly be affected is pretty deminimis for our company. Stepping back the compulsory nature I believe caught everyone by surprised. It certainly caught us by surprise. But it does signal that CMS is committed to moving the industry into some kind of coordinated care and coordinated payment system. The Affordable Care Act got a lot of attention with respect to increasing coverage for those who did not have any insurance and most of the focus appropriately was on – what that meant for the uninsured. But certainly as we look at the Affordable Care Act, our attention was on those provisions that addressed changes to the Medicare program and the creation of the Center for Medicare and Medicaid Innovation was one that definitely got our attention and the authority that the secretary has to make these changes was I think in over look component of the Affordable Care Act. But that’s a reality wherein. Frankly, we think there is an opportunity for us particularly in those markets where we have both hospital and a home health presence. If we can get certain regulatory release and that’s certainly where we’re going to be proposing. We think that this could create a market share gain opportunity for us with respect to knees and hips. As you know it’s a pretty small amount of business today were really limited by the 60% rule in terms of the kinds of patients knee and hip patients that we can treat. But we do believe that we can compete very effectively with any rehap provider be it other IRF or other SNF in getting these patients home and getting them back into some semblance of an independent life. So the devils in the detail, we will be approaching CMS with some thoughts on pricing flexibility, so that we have the ability to work with our Encompass Home Heath partner and approach the acute care hospitals with some innovative ideas. It’s really too early to talk about what those details look like, but if it’s going to be driven by who can provide the best care on the most cost effective basis, we think we’ve got the pieces to do that -- the piece in place to be able to do that.

Okay, thanks. And then maybe my follow-up would be -- it sounds like you're making decent progress of entering home health in the markets where you have IRFs and no Home Health presence. Can you just give us an update how quickly you will be able to do that and what you are seeing in the marketplace in terms of opportunity for home health acquisitions?

The development pipeline in home health is very impressive, the folks at in Encompass are well known in the industry. They are well respected in the industry. Trends that we have talked about for some time, regulatory barriers to entry, quality reporting measures that may force some out pricing pressures, all of those are still in place and we think that that’s contributing to a pretty favorable development landscape for Encompass in particular in Home Health in general. So, clearly as we said before as we look at growth opportunities we will be looking to enter states and markets where we have a hospital presence but no home health presence and we believe we’re going to be able execute on that strategy going forward.

Your next question comes from the line of Josh Raskins with Barclays

Hello, Josh.

Hi. Good morning, Jay. Quick one on the medical insurance reserve boost. I'm assuming the big case was probably the minority of the increase there. So just from a run rate perspective, was any of this relating to 2014, or should we think about the $4 million maybe less whatever that big one timer was as sort of the new run rate? I know you mentioned the specialty pharma will sort of continue?

Hey, Josh, it’s Doug. So actually it was split almost evenly between the two. They were both essentially $2 million items. We don’t expect the severe claim will be repeated in the second half of the year. As I mentioned in my comments we do anticipate that at least portion of the increase in specialty drug utilization will continue. We’re anticipating about a 7% year-over-year increase in group medical expenses for the second half of the year and that’s embedded in our guidance. That’s a combination of the higher run rate and it’s also taking into effect the fact that we had some favorable adjustments to the reserve in the second of last year.

Okay. That makes sense. Got you. That's a big claim. Okay. And then on the Medicaid payer mix, I just want to better understand the impact on EBITDA, and I think you said covering variable costs. So, does this change the way you think about markets that have expanded Medicaid? I sort of look at your occupancy, it certainly seems like you've got room for some of these patients. To your point, I can't imagine it eating into any other opportunities, so I understand the impact on margin, but shouldn't we think of this as a good trend that you are seeing more people come in?

We do, frankly and even though this maybe this maybe a bit of a transition to the total population that we’re treating. At some point that anniversaries and we do get some pricing lift from Medicaid. So, at some point we’ll start to see some tailwind in terms of unit price. But yes we do believe that this is a positive development, but it’s a change. The biggest impact is that its having is on the year-over-year pricing growth. As Doug pointed out in his comments however 110 basis point delta in the pricing was attributable to SSI, so you got to put that into the equation as well. But yes, we see that incremental growth and the incremental value is being positive.

It is as I mentioned in my comments as well Josh, so because of the extreme variability in the Medicaid reimbursement rates on a per state basis it’s a question that literally needs to be address hospital by hospital looking at what the current occupancy levels are in an existing hospital and what the state Medicaid reimbursement rates area.

Got you. But I mean, so is there a way to delineate these rates? As you mentioned, the Medicaid expansion states, right, which is I think the majority of your states that you have IRFs in, is there a way to say, okay, the rates there are not adequate, or they are adequate to cover their rates, or is it, again, it doesn't sort of fall out that way?

Yes. Unfortunately it’s a mix bag in those states too. There are some states where Medicaid is expanding and the reimbursement is more than sufficient to cover our variable cost per day. And there are others where to real challenge so it’s something we’re going to be spending a lot more time digging in on and working in concert with our referral partners to understand how we can better manage that. But I think as Jay mentioned overall we do think that would be patient population which we can address as expanding is a positive thing.

Right. Okay. Perfect. Thanks.

Your next question comes from the line of Kevin Fischbeck with Bank of America

Good morning, Kevin.

Good morning. This is actually Joanna Gajuk, filling in for Kevin. Thanks for taking the question here. So just is to verify…

Good morning.

Good morning, Jay. So just to clarify the comments you made on your traditional Medicare which you said half of the year-over-year, same-store volume growth came from traditional Medicare, I just want to confirm that you meant same-store volume. And also would you characterize the traditional Medicare sort of growth rates that you experienced so far this year versus last year, whether this is kind of the way it should be, with expectation accelerating? Any color you might give there. Thank you.

I’ll answer the second part. Yes, we are very pleased with that year-over-year Medicare growth. And that is reflective of our presence in markets where there is a large concentration of Medicare enrolees, and the strategic entering of those markets over time. But yes, we’re pleased with what we’ve seen in terms of traditional Medicare.

And with regard to the clarification on my statement 50% of the total, approximately 50% of the total discharge growth was from traditional Medicare.

Great. Thanks. And just a quick follow-up. The comment you made on the proposed mandatory joint replacement bundle, you said it might be positive, net positive for the Company, because I guess you feel like applicable -- small portion of your volumes would be impacted on your IRF side, but then could you pick up some patients on the home health side, so that's why you feel like it could be positive because you don't feel like you're going to lose much but you could potentially benefit from operating the home health agency in this market, right?

Well, actually depending on how the final rule is laid out. What kind of pricing flexibility we may able to secure. Frankly we think it could be a positive for our hospitals as well. Clearly it’s going to a positive for our home health business. Encompass does an outstanding job of taking care of joint replacement patients. They’ve done that for quite a period of time. They have special programs that are devoted to that. But we think frankly that combining in those 15 markets our hospital and our rehap facility base rehap capabilities with what Encompass does and give some pricing flexibility. I think we could be a very attractive partner for the acute care hospitals to a required to participate. And I did say that we’re concerned about the precedent that the mandatory aspect of this rule. I also want to say that this is just our opinion and we’re not in the acute care world anymore, but I spend a lot of time in that acute care world. I would think that there are going to be a fair number of acute care hospitals that are looking at that January 1, 2016 deadline and saying how am I going to get there? I certainly would advocate that it will be push back a year to get the industry the opportunity to put the systems and the processes in place to be able to manage this. We’ll see how that plays out, but that’s certainly going to be one of the comments that we would be presenting as we give our comments to CMS.

Thanks. That's very helpful color as always. Thank you, Jay.

You’re welcome.

Our next question comes from the line of Dana Nentin with Deutsche Bank

Thanks, good morning.

Good morning.

Thanks for taking the call. So just going back to the pipeline, I appreciate the color that you have given, but specifically as it relates to the IRF pipeline, given the number of joint ventures you’ve announced so far this year, can you provide any color on sort of what the mix is between joint ventures and acquisitions at this point in the pipeline?

Yes. If you take Reliant out because that is such a large transaction and you just look at the development pipeline most of what we’re seeing is joint venture opportunities. And what we predicted we would see several years ago continues to play out and that is that all acute care hospitals have the wherewithal to be all things to all people and yet the industry pressures are demanding that. And so lot of the hospitals recognize that partnering with players like HealthSouth makes more sense than trying to go it on their own. And so most of what we see on the IRF side are joint venture opportunities.

Got it.

Typically if you look specifically at the IRF development projects that are listed on page six and seven beyond what it already onboard, there are seven IRF projects listed and four of those are JVs.

Got it. And then just quickly on the home health and hospice segment, can you give any sense for how much of the year-over-year revenue growth in the quarter was driven by organic factors versus M&A?

I think the best measure of the organic factors are the kind of same store equivalents on the Encompass business that I cited during my comments and to remind you of those, in Q2 for those locations that were owned by Encompass prior to 2014 it mission increased to 15.9% , recertification increased 9.3% and episodes increased to 12.2%. So the fact is we’re seeing very strong organic growth and we’re also seeing very good growth from those acquisitions that were completed by Encompass during the course of 2014, recall that they made a very significant acquisition that closed I believe late in the third quarter or early in the fourth quarter of last year that would be acquisition of the Phoenix business in Florida.

Great. Thank you.

Your next question is from the line of Sarah James with Wedbush Securities.

Good morning, Sarah.

Good morning. Thank you. I wanted to go back to the topic of the advantage of the vertically integrated model. So specifically thinking about the opportunity for IRF to charge, capture, the pre-Encompass, I think it was 8% to 9%, but now you've had six months of strengthening relations with the referring physician, so are you starting to see some traction there? And now that you have an even greater geographic overlap with the addition of Reliant, how do you think about where the capture potential could be long term?

The overlap clinically in those markets where we have both Encompass and HealthSouth is – we think it’s sort of in the early stages, but the progress that we’re making is quite good. The document that Doug refer to which helps to delineate how we will be able to work together on that clinical collaboration, now that took little while to get finalized. But that’s now being promulgated across the entire company. So, we think that those opportunities are there and we’re starting to see them, but there is more to come.

I would also again comment on couple of things here. First as Jay mentioned, those guidelines were just completed in June. But even with that I cited specifically and I’ll restate right now that in January for a little bit of context in January Encompass received 79 admissions from 21 HealthSouth IRFs. In June Encompass received 381 admissions from 35 HealthSouth IRFs and this was before we really had those protocols completely lined out. So we’re at the very beginning of the process, in fact we’re just really getting started. I’ll also note that with regard to alignment of the development pipelines, for the first half of 2015 we acquired seven new home health locations and all of those were in markets in which we have an IRF presence and given the geographic footprint of the Reliant business there’s a lot of additional overlap that’s going to come in to play there. So we think that the opportunity is increasing. There was a slight that we included in our Investor Day presentation that showed a prioritization of the clinical collaboration opportunities and I think that really helps to scope out what the potential is in that regard.

I appreciate the color. And just to follow-up, how do you think about what kind of spend may be needed over time to achieve those goals?

What kind of what?

Administrative spend to really get the different practices working together potentially staffing up. What kind of spend should we think about?

I don’t think its going to be significant. The spend will be more directed towards the establishment of clinical protocols, those clinical protocols will be established in turn by clinical experts from Encompass, clinical experts from the inpatient patient rehabilitation side that are already out there on the ground providing care today. There maybe some modest supplemental cost associated with outside consultants and so on, but I don’t envision that there would be a huge incremental cost to enhance that clinical collaboration. I think it would be much more function of using practitioners who are already on the ground doing this today, getting together, coming up with best practices, establishing those and then throughout our organization promulgating those best practices.

And I think just to elaborate that, I would envision that any incremental operating expense with regard to this strategic initiative will very quickly translate into a revenue stream. I think the spend is really the capital spend and that’s the $30 million to $40 million in agency acquisitions that we cited previously which I think continues to be a good number to use a run rate and that’s to fill in those markets where we have IRF but don’t currently operate a home health business.

Your final question comes from the line of Chad Vanacore with Stifel

Good morning, Chad.

Thanks for fitting me in this morning. So first, could you give us a little more color on the Medicare prepayment claims experience? What were the denials in the quarter, and what's your progress on the new department to deal with claims denials, and can you say that there's any improvement at this stage?

Let me take the second part. The second – their department – their new department is really aimed at enhancing the documentation by positions in our hospitals. And so – and we’re starting to see some early traction there. As we’ve said previously we do think that the rollout of our clinical information system will enhance those efforts not only for the physicians but also it will give us an opportunity to better manage and monitor the compliance with our new guideline that Lisa and her team are putting out there.

In addition, this is John Whittington. In addition to providing continuous training and education to physicians own documentation we’re also training the physicians on how to prepare for these ALJ hearings and these claims denials, so that when they come into a hearing they are really prepared to present evidence and justified the admission to begin with and we’re seeing results from that training already.

Chad, its Doug, the claims denials in second quarter were little over $18 million, that’s up about $2 million from what we’ve experienced in Q1.

All right. That's great, thanks. And just one quick one on the Social Security ratio impact and Medicare rates, how much of that $5 million is related to the current period and year to-date?

A very modest portion because it dates back to 2013, I assume I don’t have in front of me but that would be fairly ratable over what amounts to a 30 month period.

All right. Thanks a lot.

All right. Thank you.

There are no further questions at this time. I would now like to hand the floor back over to management for any further closing remarks.

Yes. Thank you. If you have additional questions, Ross and I will be available later today. Please call me at 205-969-6175. Thank you.

This concludes HealthSouth's second quarter 2015 earnings call. You may now disconnect.